tbuckley/cabot-search huggingface dataset:
Abstract 32: Improper Histone Modification Of Gene Expression In Kawasaki Disease May Influence Both Its Development And Outcome
Authors: Deniz Yeter, Ho-Chang Kuo
Journal: Circulation (2015)

Kawasaki disease (KD) is characterized by development of an autoimmune vasculitis and potential coronary artery lesions (CAL). Patients present with significantly marked expression of various immune cells and the inflammatory cells that they produce, recruit, or secrete, particularly cytokines. Concurrently, regulatory immune cells that suppress immune and inflammatory cells are significantly reduced in KD, particularly regulatory T cells (Tregs) such as CD4+CD25+FOXP3+ Tregs. Therefore, the clinical picture results from an unchecked, marked increase of immune and inflammatory cells infiltrating passed activated endothelial cells and into the vascular wall. This appears to largely be a consequence of amplified cell signaling via the Ca2+/NFAT pathway in KD, which is involved in targeted gene expression. As a result, we hypothesized that epigenetic control of gene expression through histone modifications may play a leading role in development of KD, its complications, and recovery. A previous study found significant DNA hypomethylation of CpG sites for the SOCS1 gene in KD patients (n=32), which was higher in patients without CAL. We conducted a preliminary study to widely examine epigenetic changes in DNA methylation of CpG sites before and after IVIG treatment in KD patients (n=9) using age-matched febrile controls (n=8). Our results demonstrated ≥10% differences in DNA methylation rates for 67 genes in KD patients, in addition to 10 genes with ≥15% methylation difference. Larger studies are required to accurately determine the role of epigenomic changes in KD development, in addition to investigations of the methylation reactions which regulate them (see Figure 1).
Medicine in Charleston at the time of the Revolution
Authors: J. I. Waring
Journal: JAMA (1976)

Settled670, Charleston could 1 lay no claim to medical distinction until after the first quarter of the 18th century. The usual difficulties of the early period of settlement had been met with moderate success. Among them were numerous unhappy experiences with serious disease of epidemic nature—smallpox, malaria, yellow fever, respiratory tract infection, scarlet fever, diphtheria, and dysentery—to mention the worst offenders. To combat these, the limited talents of a modest number of physicians of doubtful skill were available, although their effectiveness was restricted by the state of medical knowledge of the time. The appointment in 1712 of a health officer to inspect incoming ships did not succeed in protecting the town from imported disease. After the first quarter of the century, Charleston acquired a better quality of practitioners, including some few who displayed a scientific curiosity. Thomas Dale of England, graduate of Leyden, translator of medical treatises, later to be
Percutaneous Cholecystoscopy
Authors: K Inui, S Nakazawa, J Yoshino, K Yamao, Y Naito, E Kimoto, T Asai
Journal: Endoscopy (1989)

Since 1981, we have been conducting research on percutaneous transhepatic cholecystoscopy through the sinus tract of percutaneous cholecystostomy and this method has been employed in 72 patients with gallbladder diseases. We have already reported on percutaneous transhepatic cholecystoscopy and its usefulness for the diagnosis of early gallbladder carcinoma. Histological diagnosis was possible on the basis of cholecystoscopic biopsies in all 21 patients with gallbladder carcinoma, including eight patients with early carcinoma. Percutaneous cholecystoscopy is a reliable method for making the differential diagnosis between carcinoma and polypoid lesions of the gallbladder, and the diagnosis of cancer extension on the mucosa to the cystic duct. This method is recommended as a further and final step for the early diagnosis of gallbladder carcinoma. We performed endoscopic lithotripsy with the Nd:YAG laser or electrohydraulic lithotripter, and treated 21 patients with cholecystolithiasis. We report here on the results and features of this method as a nonsurgical treatment for cholecystolithiasis.
The Nervous System and Its Diseases; A Practical Treatise on Neurology for Physicians and Students.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical Education In China
Authors: E. Grey Dimond
Journal: JAMA (1972)

<h3>To the Editor.—</h3> The amount of correspondence resulting from my report has further convinced me that if I would just put away my stethoscope and pick up my acupuncture needle, I would be well on my way into a retirement program. In a more serious vein, I wish to reach the large number of bona fide investigators who have expressed an interest in studying acupuncture anesthesia. The entire subject is outside my field of information, and I have no personal ability or intent to take on the very necessary basic studies if this form of anesthesia is to have a place in medical practice. I have tried to inform myself through library research, and the following references<sup>1-10</sup>seem to me to have a continuing theme of information which may carry underlying explanation for the anesthesia induced by the acupuncture technique.
Itching to Find Out
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 40: Biomaterials and systems biology to guide breast cancer drug screening
Authors: Alyssa Schwartz, Lauren Barney, Lauren Jansen, Christopher Hall, Aaron Meyer, Shelly R. Peyton
Journal: Cancer Research (2019)

Abstract Improved in vitro models are needed to better understand cancer progression and bridge the gap between in vitro proof-of-concept studies, in vivo validation, and clinical application. Many methods exist to create biomaterial platforms, including hydrogels, which we use to study cells in contexts more akin to what they experience in vivo. Our lab has multiple approaches to create such biomaterials, based on combinations of poly(ethylene glycol) (PEG) with peptides and zwitterions. In this presentation, I will discuss our findings in using these cell culture environments to understand the role of the extracellular matrix (ECM) in controlling cancer cell innate drug response via adaptive signaling. Specifically, I will present data comparing the behavior of breast, prostate, and ovarian cancer cells to chemotherapy and targeted drugs when cultured as 3D spheroids, on 2D gels, and as a function of the stiffness of the tumor microenvironment. This approach uncovered that cells on 2D hydrogels and spheroids encapsulated in 3D hydrogels were less responsive to receptor tyrosine kinase (RTK)-targeting drugs sorafenib and lapatinib, but not cytotoxic drugs, compared to single cells in hydrogels and cells on plastic. We found that transcriptomic differences between these in vitro models and tumor xenografts did not reveal mechanisms of ECM-mediated resistance to sorafenib. However, a systems biology analysis of phospho-kinome data uncovered that variation in MEK phosphorylation was associated with RTK-targeted drug resistance. Using sorafenib as a model drug, we found that co-administration with a MEK inhibitor decreased ECM-mediated resistance in vitro and reduced in vivo tumor burden compared to sorafenib alone. In sum, we provide a novel strategy for identifying and overcoming ECM-mediated resistance mechanisms by performing drug screening, phospho-kinome analysis, and systems biology across multiple biomaterial environments. Our work suggests that different model systems are important for evaluating cell response to receptor tyrosine kinase inhibitors, whose efficacy depends on cell-ECM interactions. Citation Format: Alyssa Schwartz, Lauren Barney, Lauren Jansen, Christopher Hall, Aaron Meyer, Shelly R. Peyton. Biomaterials and systems biology to guide breast cancer drug screening [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 40.
Long-term Mortality After Primary Prevention for Cardiovascular Disease-Reply
Authors: Timo E. Strandberg
Journal: JAMA (1992)

<h3>In Reply.</h3> —In regard to Drs Bassler and Bassler, our study was a multifactorial prevention trial involving, in addition to hypolipidemic medications, other intervention measures. Consequently, the results can only be applied to all these measures combined, including treatment of hypertension, so that it is irrelevant to talk about the real hazard of cholesterol reduction alone. Accordingly, application of our mortality data to 60 million Americans targeted for cholesterol lowering is totally misleading. Subgroup analyses performed so far have not supported the idea that hypolipidemic treatment alone could have caused the difference in total mortality. In reply to Dr Holme, since the risk factor levels were similar in the two groups in 1985, we cannot see any special reason why they were much different after that. The death certificates were hardly biased in the intervention group because in virtually all cases without unequivocal lifetime hospital diagnosis, the cause of death
An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).
Authors: G. Scagliotti, I. Vynnychenko, Y. Ichinose, K. Park, K. Kubota, F. H. Blackhall, R. Pirker, R. Galiulin, T. Ciuleanu, O. Sydorenko, M. Dediu, Z. Papai-Szekely, N. Martinez Banaclocha, S. McCoy, B. Yao, Y. J. Hei, D. R. Spigel
Journal: Journal of Clinical Oncology (2011)

LBA7512 The full, final text of this abstract will be available in Part II of the 2011 Annual Meeting Proceedings, distributed onsite at the Meeting on June 4, 2011, and as a supplement to the June 20, 2011, issue of Journal of Clinical Oncology.
SCHENK'S THEORY IN PRACTICE.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RELAXATION OF RESTRICTIONS ON PRESCRIBING OF LIQUOR
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The muddle of diets for gastrointestinal disorders
Authors: R. M. Donaldson
Journal: JAMA (1973)

What should the patient with a common gastrointestinal disorder eat? Only casual perusal of any hospital diet manual is needed to recognize that neither patient nor physician has any clear answer. More than a decade ago a detailed report by the AMA Council on Foods and Nutrition pointed out that diet therapy for most afflictions of the digestive tract is based on unsubstantiated opinion and tradition and that there was an urgent need to learn "exactly what foods do within the human digestive system."<sup>1</sup>Unfortunately, the situation today remains as muddled as ever. Dietary treatment of peptic ulcer provides a good example of the problem. Those who advocate dietary restrictions for ulcer patients<sup>2</sup>urge that only "bland" foods be allowed. In general that restriction has been implemented by presenting the patient with foods of a particular color (white), consistency (soft), and taste (mild) that fit the physician's or
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
Authors: S.M. Swain, A. Schneeweiss, L. Gianni, J.J. Gao, A. Stein, M. Waldron-Lynch, S. Heeson, M.S. Beattie, B. Yoo, J. Cortes, J. Baselga
Journal: Annals of Oncology (2018)

Ann Oncol 2017; 28: 761–768 (doi: 10.1093/annonc/mdw695) In the original article, the following funding information was omitted: This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. This has now been added. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumabAnnals of OncologyVol. 28Issue 4PreviewPertuzumab disrupts heterodimerization between human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), HER3, and HER4. Thus, pertuzumab could result in adverse events similar to those observed with EGFR antagonists, such as diarrhea. We report the incidence and severity of diarrhea observed with pertuzumab in the CLEOPATRA, NeoSphere, and TRYPHAENA studies. Full-Text PDF Open Archive
Aortic Valvular Surgery with Artificial Valves: Analysis of First 100 Patients
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MEMBERS' REUNIONS.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HOUT-17. ELDERLY PATIENTS &gt;65YEARS OF AGE WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME GAIN LIFE TIME FROM TREATMENT WITH TUMOR TREATING FIELDS AND TEMOZOLOMIDE
Authors: Gregory Guzauskas, Bruce CM Wang, Christina Proescholdt
Journal: Neuro-Oncology (2018)

The EF-14 trial was the first randomized controlled trial to report a survival benefit for newly diagnosed GBM patients in more than a decade with a survival rate greater than 10% at 5-years. A post hoc subgroup analysis of the elderly (>65 years) EF-14 population showed the greatest survival benefit in this subgroup (HR = 0.51) with survival at 5-years of 15% for patients treated with TTFields and maintenance TMZ compared to no survivors in the TMZ alone arm. MATERIALS/ An integrated survival model was calculated, incorporating Kaplan-Meier data of the subgroup of over 65 years GBM patients from the EF-14 Trial with epidemiological data on long-term GBM survival. Future survival benefits were discounted at a rate of 3%. We also performed sensitivity analyses of the results and compared the results of our integrated survival model to regression based extrapolations of the trial data. Elderly patients treated with TTFields and TMZ achieved an undiscounted mean lifetime survival of 3.66 years compared to 1.32 years for patients treated with TMZ alone, resulting in a gain of 2.34 life years for TTFields plus TMZ. After application of the 3% discount rate for future survival benefits, the resulting life time survival is 3.04 vs. 1.29 life years respectively, resulting in 1.75 incremental life years gained. In the subgroup of elderly patients of the EF-14 Trial treatment with TTFields plus TMZ resulted in a substantial increase of the mean lifetime survival of 1,75 life years compared to treatment with TMZ alone, despite the older age of the patients with a naturally lower potential for long-term survival. These results together with the low incidence of adverse events in the EF-14 trial indicate that it may be appropriate to opt for TTFields treatment in newly diagnosed GBM patients 65 years and older.
Inherited Cardiomyopathies
Authors: Franklin H. Epstein, Daniel P. Kelly, Arnold W. Strauss
Journal: New England Journal of Medicine (1994)

Cardiomyopathy is an important cause of morbidity and mortality throughout the world in children and adults. In contrast to secondary causes of cardiomyopathy, such as hypertension and ischemic heart disease, the causes and pathogenesis of primary myocardial disease are poorly understood. The term “idiopathic cardiomyopathy” is therefore often used to describe primary myocardial disease. The annual incidence of idiopathic dilated cardiomyopathy in the United States and Europe is estimated to range from 2 to 8 cases per 100,0001. Overall, the survival of patients with idiopathic cardiomyopathy is poor (only 50 to 60 percent at two years).Familial analyses have . . .
American Indian medicine: paternalism and pluralism
Authors: J. E. Smith
Journal: JAMA (1986)

<h3>To the Editor.—</h3> I wonder if anyone else gets tired of hearing about the noble Native American culture and how beautiful, pure, and in harmony with the world it was until the rude, crude, modern "American" culture destroyed it. Your recent article on American Indian medicine<sup>1</sup>approaches the subject in the usual "noble Indian/wicked white man" way. Having worked on an Indian reservation associated with public health for two years, I am by no means an expert on the subject; but neither am I ignorant of the many facets of the problem. It is of primary importance to understand that there is no one Native American culture. To group, therefore, a bunch of doctors who have at least one-eighth Indian blood together and make them represent all the Indian tribes is naive and dooms their efforts to improve the lot of Indians. The tremendous diversity in cultural backgrounds of different